Predictive Biomarkers for Neoadjuvant Chemotherapy Response in Muscle-Invasive Bladder Cancer: A survey

Bladder cancer is the most prevalent urinary tract malignancy and is associated with the highest treatment cost among cancers. The standard therapy for patients with muscle-invasive bladder cancer is the radical cystectomy. Nevertheless, there is a high mortality rate within five years after cystectomy. Neoadjuvant chemotherapy of cisplatin-based combinations have been shown to increase the overall survival of the patients. However, not all patients get benefits from the chemotherapy due to resistance to cisplatin, and there is no reliable biomarker to identify the non-responders. Therefore there is a need to identify chemoresistant patients, by finding cisplatin-response biomarkers, to avoid unnecessary surgery delay and drug toxicity. In this paper, we present a review of the current predictive biomarkers to neoadjuvant chemotherapy response that aim to provide a way of individualized therapy in muscle invasive bladder cancer. Furthermore, we will discuss the effectiveness and limitations of these biomarkers. Finally, future trends in this area of research will be discussed.

[1]  Sheng Zhou,et al.  Repression of GRIM19 expression potentiates cisplatin chemoresistance in advanced bladder cancer cells via disrupting ubiquitination-mediated Bcl-xL degradation , 2018, Cancer Chemotherapy and Pharmacology.

[2]  Yair Lotan,et al.  Multicenter assessment of neoadjuvant chemotherapy for muscle-invasive bladder cancer. , 2015, European urology.

[3]  Gangning Liang,et al.  Rewiring of cisplatin-resistant bladder cancer cells through epigenetic regulation of genes involved in amino acid metabolism , 2018, Theranostics.

[4]  J Alfred Witjes,et al.  LINC00857 expression predicts and mediates the response to platinum‐based chemotherapy in muscle‐invasive bladder cancer , 2018, Cancer medicine.

[5]  Shan Zhong,et al.  CIP2A depletion potentiates the chemosensitivity of cisplatin by inducing increased apoptosis in bladder cancer cells , 2018, Oncology reports.

[6]  C. Mathers,et al.  Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012 , 2015, International journal of cancer.

[7]  Carsten Wiuf,et al.  Comprehensive Genome Methylation Analysis in Bladder Cancer: Identification and Validation of Novel Methylated Genes and Application of These as Urinary Tumor Markers , 2011, Clinical Cancer Research.

[8]  Yair Lotan,et al.  Bladder cancer , 2020, Nature Reviews Disease Primers.

[9]  Jindrich Cinatl,et al.  Chemoresistance is associated with increased cytoprotective autophagy and diminished apoptosis in bladder cancer cells treated with the BH3 mimetic (−)-Gossypol (AT-101) , 2015, BMC Cancer.

[10]  J. Witjes,et al.  MUSCLE-INVASIVE AND METASTATIC BLADDER CANCER , 2016 .

[11]  Jun Xiao,et al.  miR‑22‑3p enhances multi‑chemoresistance by targeting NET1 in bladder cancer cells. , 2018, Oncology reports.

[12]  Roland L Dunbrack,et al.  Defects in DNA Repair Genes Predict Response to Neoadjuvant Cisplatin-based Chemotherapy in Muscle-invasive Bladder Cancer. , 2015, European urology.

[13]  Nicholas J Vogelzang,et al.  Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. , 2003, The New England journal of medicine.

[14]  P. Hanawalt,et al.  Transcription-coupled DNA repair: two decades of progress and surprises , 2008, Nature Reviews Molecular Cell Biology.

[15]  P. Cooke,et al.  Bcl‐2 expression identifies patients with advanced bladder cancer treated by radiotherapy who benefit from neoadjuvant chemotherapy , 2000, BJU international.

[16]  P. Tchounwou,et al.  Cisplatin in cancer therapy: molecular mechanisms of action. , 2014, European journal of pharmacology.

[17]  S. Nilsson,et al.  Positron emission tomography with L-methyl-11C-methionine in the monitoring of therapy response in muscle-invasive transitional cell carcinoma of the urinary bladder. , 1994, British journal of urology.

[18]  Qiang Li,et al.  ERCC2 Helicase Domain Mutations Confer Nucleotide Excision Repair Deficiency and Drive Cisplatin Sensitivity in Muscle-Invasive Bladder Cancer , 2018, Clinical Cancer Research.

[19]  Hai-ge Chen,et al.  Somatic FGFR3 Mutations Distinguish a Subgroup of Muscle-Invasive Bladder Cancers with Response to Neoadjuvant Chemotherapy , 2018, EBioMedicine.

[20]  Shahrokh F. Shariat,et al.  An Epigenomic Approach to Improving Response to Neoadjuvant Cisplatin Chemotherapy in Bladder Cancer , 2016, Biomolecules.

[21]  Sten Nilsson,et al.  Neoadjuvant cisplatinum based combination chemotherapy in patients with invasive bladder cancer: a combined analysis of two Nordic studies. , 2004, European urology.

[22]  S. Groshen,et al.  Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  J. Baselga,et al.  Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[24]  Stephen A Boorjian,et al.  Oncologic Outcomes for Patients with Residual Cancer at Cystectomy Following Neoadjuvant Chemotherapy: A Pathologic Stage-matched Analysis. , 2017, European urology.

[25]  Rosalie C Sears,et al.  Serine 62-Phosphorylated MYC Associates with Nuclear Lamins and Its Regulation by CIP2A Is Essential for Regenerative Proliferation. , 2015, Cell reports.

[26]  S C Chen,et al.  Accumulation of nuclear p53 and tumor progression in bladder cancer. , 1994, The New England journal of medicine.

[27]  M. Lai,et al.  Various forms of mutant p53 confer sensitivity to cisplatin and doxorubicin in bladder cancer cells. , 2001, The Journal of urology.

[28]  S. Gabriel,et al.  Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma. , 2014, Cancer discovery.

[29]  M. Fouda,et al.  Gene expression of excision repair cross-complementation group 1 enzyme as a novel predictive marker in patients receiving platinum-based chemotherapy in advanced bladder cancer , 2018 .

[30]  Ronald C Chen,et al.  Muscle‐invasive bladder cancer: evaluating treatment and survival in the National Cancer Data Base , 2014, BJU international.

[31]  J. Witjes,et al.  EAU guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2013 guidelines. , 2014, European urology.

[32]  Peng Zhang,et al.  MiR-22 suppresses the proliferation and invasion of gastric cancer cells by inhibiting CD151. , 2014, Biochemical and biophysical research communications.

[33]  Saiful Miah,et al.  Distinct microRNA alterations characterize high- and low-grade bladder cancer. , 2009, Cancer research.

[34]  Naoya Masumori,et al.  Epigenetic silencing of miR-200b is associated with cisplatin resistance in bladder cancer , 2018, Oncotarget.

[35]  Juan Ni,et al.  Response of MiRNA-22-3p and MiRNA-149-5p to Folate Deficiency and the Differential Regulation of MTHFR Expression in Normal and Cancerous Human Hepatocytes , 2017, PloS one.

[36]  Joaquim Bellmunt,et al.  Optimisation of the size variation threshold for imaging evaluation of response in patients with platinum-refractory advanced transitional cell carcinoma of the urothelium treated with vinflunine. , 2012, European journal of cancer.

[37]  Kazutaka Saito,et al.  Clinical Investigation : Genitourinary Cancer Role of Diffusion-Weighted Magnetic Resonance Imaging in Predicting Sensitivity to Chemoradiotherapy in Muscle-Invasive Bladder Cancer , 2012 .